Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Arcutis Biotherapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Arcutis Biotherapeutics şirketinin toplam hissedar öz sermayesi $186.4M ve toplam borcu $203.8M olup, bu da borç-öz sermaye oranını 109.3% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $444.8M ve $258.3M dir.

Anahtar bilgiler

109.3%

Borç/özkaynak oranı

US$203.81m

Borç

Faiz karşılama oranı	n/a
Nakit	US$362.44m
Eşitlik	US$186.43m
Toplam yükümlülükler	US$258.33m
Toplam varlıklar	US$444.76m

Son finansal sağlık güncellemeleri

Recent updates

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry

Sep 23

Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely

Aug 22

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Jul 17

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Popularity With Investors Is Under Threat From Overpricing

Jun 21

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

May 24

Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory

May 20

Arcutis Biotherapeutics: Betting Big On Zoryve

May 01

New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Apr 25

Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues

Mar 03

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates

Mar 02

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up

Feb 28

Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture

Jan 31

Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%

Oct 23

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

Aug 13

Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57

Aug 11

Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?

May 02

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Dec 18

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ARQT 'nin kısa vadeli varlıkları ( $434.6M ) kısa vadeli yükümlülüklerini ( $51.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: ARQT şirketinin kısa vadeli varlıkları ( $434.6M ) uzun vadeli yükümlülüklerini ( $207.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ARQT şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: ARQT şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 109.3% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ARQT şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: ARQT tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Arcutis Biotherapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Recent updates

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry

Arcutis Biotherapeutics, Inc. Announces Publication of ZORYVE (Roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology

Arcutis Biotherapeutics, Inc. Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely

Consensus estimates of losses per share improve by 12%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

President recently sold US$131k worth of stock

Forecast to breakeven in 2026

Arcutis Biotherapeutics, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Arcutis Launches ZORYVE (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis

Arcutis Biotherapeutics, Inc. Submits Supplemental New Drug Application for Zoryve (Roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and over

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Arcutis Biotherapeutics, Inc. Announces the U.S. Food and Drug Administration's Approval of the Supplemental New Drug Application for ZORYVE (Roflumilast) Cream

Insufficient new directors

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Popularity With Investors Is Under Threat From Overpricing

Senior VP & Chief Medical Officer exercised options and sold US$201k worth of stock

Senior VP & Chief Medical Officer recently sold US$435k worth of stock

Senior VP & Chief Medical Officer notifies of intention to sell stock

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

Consensus revenue estimates increase by 36%

Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Arcutis Biotherapeutics, Inc. Announces Journal of Clinical and Aesthetic Dermatology Publishes the Outcomes of a Comprehensive Evaluation by an Expert Dermatology

President notifies of intention to sell stock

Arcutis Biotherapeutics: Betting Big On Zoryve

Arcutis Biotherapeutics, Inc. to Report Q1, 2024 Results on May 14, 2024

Arcutis Biotherapeutics, Inc., Annual General Meeting, Jun 14, 2024

New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Consensus revenue estimates increase by 10%

Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes

Arcutis Presents Late-Breaking Data from INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 At the American Academy of Dermatology Annual Meeting

President notifies of intention to sell stock

Consensus revenue estimates increase by 24%

Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates

Arcutis Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150.000003 million.

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 18% to US$13.33

Arcutis Biotherapeutics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Arcutis Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture

Arcutis Biotherapeutics, Inc. Announces New Subgroup Analysis Highlighting That Adults and Adopts ZoryVE Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids

Arcutis Biotherapeutics, Inc. Announces New Individual Patient Response Data Showed at the 2024 Winter Clinical Dermatology Conference - Hawaii

FDA Approves Arcutis' ZORYVE®? (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

President exercised options to buy US$118k worth of stock.

Arcutis Biotherapeutics, Inc. Announces FDA Accepts Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6

Consensus revenue estimates increase by 19%

Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%

New major risk - Shareholder dilution

Arcutis Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $99.99925 million.

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 10%

Arcutis Biotherapeutics, Inc. Presents Positive Patient-Reported Outcome Data from the Pivotal Arrector Phase 3 Trial in Scalp and Body Psoriasis At European Academy of Dermatology and Venereology (Eadv) Congress

Price target decreased by 14% to US$37.86

Arcutis Biotherapeutics, Inc. Announces FDA Approves ZORYVE (Roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11

Arcutis Biotherapeutics, Inc. Announces Executive Changes

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (Ad)

Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes, Effective August 31, 2023

Consensus revenue estimates increase by 26%

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57

New minor risk - Financial position

Price target decreased by 8.5% to US$41.71

Arcutis Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Arcutis Announces Zoryve® (Roflumilast) Cream 0.3% Included in Preferred Position on National Formularies for CVS Caremark

Arcutis Biotherapeutics, Inc. Announces Executive Changes

Price target decreased by 9.2% to US$45.50

Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?

Director exercised options and sold US$104k worth of stock

Director exercised options and sold US$88k worth of stock

Director exercised options and sold US$130k worth of stock